Rocket Lab’s Iridium Collar Locks the Stock in a $67.50 Squeeze
Published on 07/17/2026 at 15:53 | Redaktion boerse-global.de
The mechanics of the Iridium Communications takeover have turned Rocket Lab’s share price into a financial instrument that tracks merger terms rather than launch milestones. By Friday’s close, the stock had fallen 2.54% to €57.60, dragging its weekly loss to nearly 19%. Earlier in the week, an intraday dip of 0.85% to €58.60 had already marked a 17.46% weekly decline. The relative?strength index, at 28.9 in one calculation and 29.5 in another, confirms a deeply oversold condition — one that reflects jitters over a deal that is both strategically bold and operationally risky.
At the heart of the sell?off is a so?called collar structure embedded in the $8 billion acquisition. If Rocket Lab’s volume?weighted average price sinks below $67.50, the number of shares Iridium’s stockholders ultimately receive will shift, altering the economics of the transaction for existing Rocket Lab holders. The market is now treating the stock as acquisition currency, not as a pure bet on rocket technology. That perception was reinforced by Piper Sandler, which initiated coverage with a Neutral rating and an $83 price target. Analyst Alexander Potter instead prefers AST SpaceMobile, citing a cheaper valuation and a clearer path to EBITDA profitability.
Yet not everyone on Wall Street is bearish. Morgan Stanley and Cantor Fitzgerald both maintain Overweight ratings, with Cantor pegging a $96 target. KGI Securities launched coverage in June at Neutral with a $105 target, while Weiss Ratings remains the most pessimistic with a Sell (D?). Roth?MKM’s Suji DeSilva recently raised his target from $100 to $130, arguing that the tie?up with Iridium strengthens Rocket Lab’s competitive position against larger rivals.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The financing burden amplifies the anxiety. Rocket Lab has secured a $3.6 billion bridge loan from Deutsche Bank and Wells Fargo — 2.4 times the cash and marketable securities the company held at the end of March. The total enterprise value of the deal is roughly $8 billion, paid partly in cash and partly in stock. The dilution from the equity component, combined with the company’s recent net loss, has spooked investors who wonder how a business that is still burning cash can service a multibillion?dollar liability.
Technical indicators offer little comfort. The 50?day moving average sits at €93.61 and the 200?day average at €67.32; the current price is below both. Support near $65 is seen as the last line of defense, while resistance in the $75 to $86 zone must be reclaimed to change the chart narrative. Adding to the unease, insider filings show that executives, including the chief financial officer, have been selling shares steadily for months, with no open?market purchases in the past six months.
Underneath the financial turbulence, Rocket Lab continues to push its next?generation Neutron rocket toward a first flight planned for the later part of 2026. The company recently described a propulsion milestone as “critical preparation” for the debut, though it acknowledges that complexity could cause further delays. R&D spending on the program jumped 46% year over year to $80.5 million in the first quarter.
Until the Iridium deal’s financing questions are answered clearly, the collar’s $67.50 floor will remain the market’s focal point. Whether Rocket Lab can stabilize above that level will determine not only the stock’s near?term direction but also how many shares Iridium’s owners ultimately pocket. The strategic logic of acquiring a global satellite?communications network — with recurring revenue, spectrum assets, and exposure to defense, aviation, maritime, and IoT markets — remains intact, but for now, the price action is all about the fine print.
Ad
Rocket Lab Stock: New Analysis - 17 July
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
